Environmental risk assessment data
This section provides ERA data relating to our medicines.
View the background information about the criteria we use for the risk assessment.
The tables below provides an overview of the environmental risk of AstraZeneca’s medicines. This information will be updated, if appropriate, as new data become available.
Cardiovascular
For information on the individual pharmaceutical click on the compound name in the table below.
| Brand name | Generic name | Therapy area | Environmental Risk |
|---|---|---|---|
| Tenormin, Tenormine, Prenormine, Atenol | Atenolol (PDF 151kb) | Cardiovascular | Insignificant |
| Nif-Ten (atenolol - nifedipine) | Atenolol (PDF 151kb) | Cardiovascular | Insignificant |
| Tenoretic (atenolol - chlorthalidone) | Atenolol (PDF 151kb) | Cardiovascular | Insignificant |
| Atacand | Candesartan cilexetil (PDF 237kb) | Cardiovascular | Insignificant |
| Atacand Plus (candesartan cilexetil – hydrochlorothiazide) | Candesartan cilexetil (PDF 237kb) | Cardiovascular | Insignificant |
| Tenoretic (atenolol - chlorthalidone) | Chlorthalidone (PDF 150kb) | Cardiovascular | * |
| Forxiga** | Dapagliflozin (PDF 129kb) | Cardiovascular | Insignificant |
| Lexxel (enalapril maleate - felodipine) | Enalapril Maleate (PDF 153kb) | Cardiovascular | * |
| Plendil, Modip, Splendil, Munobal, Flodil | Felodipine (PDF 162kb) | Cardiovascular | Low |
| Unimax (felodipine - ramipril) | Felodipine (PDF 162kb) | Cardiovascular | Low |
| Lexxel (enalapril maleate - felodipine) | Felodipine (PDF 162kb) | Cardiovascular | Low |
| Logimax (felodipine-metoprolol) | Felodipine (PDF 162kb) | Cardiovascular | Low |
| Zestoretic (lisinopril dihydrate - hydrochlorothiazide) | Hydrochlorothiazide (PDF 152kb) | Cardiovascular | Insignificant |
| Atacand Plus (candesartan cilexetil – hydrochlorothiazide) | Hydrochlorothiazide (PDF 152kb) | Cardiovascular | Insignificant |
| Imdur, Coleb-Duriles, Duronitrin, Monodur, Pertil Retard, Promocard 60 Durettes | Isosorbide-5-mononitrate (PDF 140kb) | Cardiovascular | * |
| Zestoretic (lisinopril dihydrate - hydrochlorothiazide) | Lisinopril Dihydrate (PDF 117kb) | Cardiovascular | Insignificant |
| Zestril | Lisinopril Dihydrate (PDF 117kb) | Cardiovascular | Insignificant |
| Logimax (felodipine-metoprolol) | Metoprolol Succinate (PDF 147kb) | Cardiovascular | Low |
| Seloken ZOK, Toprol-XL, Betaloc ZOK, Betaloc. Seloken | Metoprolol Succinate (PDF 147kb) | Cardiovascular | Low |
| Nif - Ten (atenolol - nifedipine) | Nifedipine (PDF 150kb) | Cardiovascular | * |
| Inderal, Inderal LA, Avlocardyl, Avlocardyl retard, Dociton, Inderalici, Sumial | Propranolol Hydrochloride (PDF 247kb) | Cardiovascular | Low |
| Unimax (felodipine - ramipril) | Ramipril (PDF 142kb) | Cardiovascular | Insignificant |
| Crestor | Rosuvastatin Calcium (PDF 249kb) | Cardiovascular | Insignificant |
| Onglyza** | Saxagliptin (PDF 139kb) | Cardiovascular | Insignificant |
| Brilinta, Brilique | Ticagrelor (PDF 241kb) | Cardiovascular | Insignificant |
*Limited data available. See pdf document.
**ONGLYZA™ and FORXIGA™ have been developed by an alliance between AstraZeneca and Bristol-Myers Squibb.
Click here (PDF 1096kb) to download all available environmental data and supporting information in the Cardiovascular therapy area.
Gastrointestinal
For information on the individual pharmaceutical click on the compound name in the table below.
| Brand name | Generic name | Therapy area | Environmental Risk |
|---|---|---|---|
| Entocort | Budesonide (PDF 158kb) | Gastrointestinal | Insignificant |
| Nexium | Esomeprazole and Omeprazole (PDF 136kb) | Gastrointestinal | Insignificant |
| Losec, Gastroloc, Mopral, Omepral, Prilosec | Esomeprazole and Omeprazole (PDF 136kb) | Gastrointestinal | Insignificant |
Infection
For information on the individual pharmaceutical click on the compound name in the table below.
| Brand name | Generic name | Therapy area | Environmental Risk |
|---|---|---|---|
| Merrem/Meronem | Meropenem (PDF 126kb) | Infection | Insignificant |
| Zinforo* | Ceftaroline (PDF 108kb) | Infection | Insignificant |
* Zinforo™ has been developed by an alliance between AstraZeneca and Forest.
Neuroscience
For information on the individual pharmaceutical click on the compound name in the table below.
| Brand name | Generic name | Therapy area | Environmental Risk |
|---|---|---|---|
| Marcaine/Sensorcaine | Bupivacaine Hydrochloride (PDF 162kb) | Neuroscience | * |
| Xylocaine | Lidocaine Hydrochloride Monohydrate (PDF 111kb) | Neuroscience | Insignificant |
| Carbocaine | Mepivacaine Hydrochloride (PDF 143kb) | Neuroscience | * |
| Citanest | Prilocaine Hydrochloride (PDF 167kb) | Neuroscience | Insignificant |
| Diprivan | Propofol (PDF 241kb) | Neuroscience | Low |
| Seroquel | Quetiapine Fumarate (PDF 141kb) | Neuroscience | Insignificant |
| Naropin | Ropivacaine Hydrochloride Monohydrate (PDF 108kb) | Neuroscience | Insignificant |
| Zomig, Zomig Rapimelt, Zomig Nasal Spray, AscoTop, Zomigon | Zolmitriptan (PDF 132kb) | Neuroscience | Insignificant |
*Limited data available. See pdf document.
Click here (PDF 636kb) to download all available environmental data and supporting information in the Neuroscience therapy area.
Oncology
For information on the individual pharmaceutical click on the compound name in the table below.
| Brand name | Generic name | Therapy area | Environmental Risk |
|---|---|---|---|
| Arimidex | Anastrozole (PDF 124kb) | Oncology | Insignificant |
|
Casodex, |
Bicalutamide (PDF 122kb) | Oncology | Insignificant |
| Faslodex | Fulvestrant (PDF 137kb) | Oncology | Low |
| Iressa | Gefitinib (PDF 150kb) | Oncology | Insignificant |
| Zoladex | Goserelin (PDF 107kb) | Oncology | Insignificant |
|
Nolvadex, |
Tamoxifen (PDF 197kb) | Oncology | Insignificant |
| Caprelsa | Vandetanib (PDF 125kb) | Oncology | Insignificant |
Respiratory
For information on the individual pharmaceutical click on the compound name in the table below.
| Brand name | Generic name | Therapy area | Environmental Risk |
|---|---|---|---|
| Bambec, Oxeol | Bambuterol Hydrochloride (PDF 93kb) | Respiratory | Insignificant |
| Pulmicort, Spirocort, Rhinocort | Budesonide (PDF 158kb) | Respiratory | Insignificant |
| Symbicort (budesonide – formoterol) | Budesonide (PDF 158kb) | Respiratory | insignificant |
| Oxis | Formoterol Fumarate Dihydrate (PDF 157kb) | Respiratory | Insignificant |
| Symbicort | Formoterol Fumarate Dihydrate (PDF 157kb) | Respiratory | insignificant |
| Symbicort (budesonide – formoterol) | Formoterol Fumarate Dihydrate (PDF 157kb) | Respiratory | insignificant |
| Bricanyl | Terbutaline Sulphate (PDF 109kb) | Respiratory | Insignificant |
| Accolate, Accoleit, Vanticon | Zafirlukast (PDF 134kb) | Respiratory | Insignificant |
Go back to...
Next section
Pharmaceuticals in the environment
We are committed to understanding the wider exposure and presence of pharmaceuticals in the environment.
Read moreProduct environmental improvement
Our objective is to continue to improve the environmental profile of our products by various means.
Read more